Advertisement
Hosting the call will be Paul E. Freiman, President and Chief ExecutiveOfficer, and Matthew M. Loar, Vice President and Chief Financial Officer. Thedetails for the call are as follows:
Advertisement
About Neurobiological Technologies, Inc.
Neurobiological Technologies, Inc., (Nasdaq: NTII) is a biopharmaceuticalcompany focused on developing novel, first-in-class agents for central nervoussystem conditions and other serious unmet medical needs. The Company's mostadvanced product candidate, Viprinex(TM) (ancrod), is in Phase 3 clinicaltesting as a novel investigational drug for the treatment of acute ischemicstroke. Viprinex has multiple mechanisms of action and is specificallydesigned to extend the time period that patients can be treated after theonset of a stroke. Acute ischemic stroke is one of the most prevalent,debilitating and costly diseases in the world for which there are fewacceptable treatment options. NTI also has early-stage development programsfor Alzheimer's and Huntington's diseases and rights to receive payments on anapproved drug for Alzheimer's disease and an investigational drug in Phase 3trials for brain swelling.Live Call: -- Date: Thursday, November 6, 2007 -- Time: 10:30 a.m. ET, 9:30 a.m. CT, 7:30 a.m. PT -- Dial-in number: 800-309-1245 (U.S.) 719-457-2080 (International) Webcast of Call: -- A live webcast can be accessed online by going to: http://investor.shareholder.com/ntii/events.cfm Telephonic Replay: (Archived for 90 days) A playback of the conference call will be available from 1:30 PM November 6 (ET) through midnight November 13 (ET). Replay number: 888-203-1112 (U.S. and Canada) / 719-457-0820 (international). Replay access code: 8094663.
SOURCE Neurobiological Technologies, Inc.
